Respiratory syncytial virus (RSV) is a single-stranded RNA virus that is well recognized as a cause of significant morbidity and mortality among children. Its impact on adults has been increasingly recognized with the wider use of molecular testing of adult patients presenting with respiratory tract infections. It has been estimated that RSV infects 3%-10% of adults annually.
as pneumonia. 2 RSV has been estimated to cause 177 525 excess hospitalizations each year and 14 000 excess deaths, in the United
States. 1, 3 Risk factors for more severe disease include old age (>65 years), solid organ (especially lung) transplant, hematopoietic stem cell transplant, and those with underlying lung disease. 4 Among nursing home residents, RSV causes significant numbers of hospitalizations and deaths each winter. 5 One study found that 12.5% of elderly patients hospitalized for an influenza-like illness had RSV detected. 6 Unlike influenza, there are no vaccines or antivirals approved for the prevention or treatment of RSV in adults. Palivizumab, a humanized monoclonal antibody against the RSV F glycoprotein, is approved for the prevention of RSV in select infants and children but has not been approved in adults as it has not been widely studied. 1, 7 Several live attenuated and sub-unit RSV vaccines are in advanced stages of development. 6, 8 Aerosolized ribavirin is approved for the treatment of hospitalized infants and young children while aerosolized, oral, and intravenous ribavirin has been used selectively in immunocompromised adults with RSV with variable results. 9 ,10 RSV-containing antibody preparations (monoclonal or intravenous immunoglobulins)
have also been used in conjunction with ribavirin. 11 Currently, two small molecule drugs, presatovir (GS-5806, a fusion inhibitor) and lumicitabine (ALS-008176, a polymerase inhibitor), are undergoing phase 2 studies in hospitalized and immunocompromised adults (ClinicalTrials.gov Identifiers: NCT02135614, NCT02254421, and NCT02254408). [12] [13] [14] In addition, several other RSV-active antivirals are in late pre-clinical and phase 1 development and hold promise for the prevention and treatment of RSV.
15
The burden of RSV infections in immunocompromised adults that are non-HSCT is not well known. 16 Most epidemiologic studies of RSV in hospitalized adults have been retrospective single-center studies covering a single or few seasons. 2, 17, 18 This retrospective cohort study was conducted to better define the epidemiology and outcomes of RSV in hospitalized adults over multiple seasons.
| ME THODS

| Patient identification
After IRB approval, a retrospective cohort study on adults hospitalized with an RSV infection was conducted. All patients admitted to either of the participating hospitals at our institution (Northwestern 
| Definitions
Each season was defined as May 1 through April 30 of the next year.
Severe illness was defined as a patient who was given non-invasive positive-pressure ventilation (NIPPV), intubated, or admitted to the ICU. The presence of abnormal imaging was defined as the presence of pulmonary infiltrates described by a radiologist on a chest X-ray or computed tomography (CT) scan of the chest. Nosocomial RSV infection defined as cases where symptoms began while a patient was in a hospital or other healthcare facility for ≥72 hours prior to a positive test for RSV. 
| Statistical analysis
| RE SULTS
| Demographics
During the 6-year study period, a total of 489 hospitalized RSV cases 10 (18) 11 (20) 43 (80) 22 (48) 24 (52) 37 (67) 18 (33) 34 (30) 81 (70) 78 (48) 86 ( 3 (30) 6 (55) 23 (53) 12 (55) 13 (54) 18 (49) 8 (44) 17 (50) 38 (47) 32 (41) 40 ( 3 (30) 1 (9) 7 (16) 3 (14) 4 (17) 6 (16) 2 (11) 6 (18) 17 (21) 23 (29) 21 ( 15 (63) 11 (30) 8 (44) 16 (47) 36 (44) 28 (36) 25 (29) 194 BMI <20
10 (22) 1 (10) 0 (0) 2 (5) 3 (14) 2 (8) 1 (3) 1 (6) 3 (9) 7 (9) 8 (10) 8 (9) 46 20-24.99
10 (22) 0 (0) 3 (27) 17 (40) 8 (36) 7 (29) 11 (30) 4 (22) 8 (24) 19 (23) 14 (18) 21 (24) 122
25-29.99
13 (29) 3 (30) 2 (18) 14 (33) 2 (9) 6 (25) 4 (11) 6 (33) 8 (24) 22 (27) 22 (28) 23 (26) 125 30-34.99 3 (7) 3 (30) 1 (9) 4 (9) 5 (23) 7 (29) 8 (22) 3 (17) 5 (15) 9 (11) 12 (15) 13 (15) 73 35-39.99
1 (2) 2 (20) 1 (9) 0 (0) 2 (9) 0 (0)
4 (11) 1 (6) 3 (9) 8 (10) 8 (10) 13 (15) 43 >40 6 (13) 0 (0) 3 (27) 5 (12) 2 (9) 1 (4) 8 (22) 3 (17) 6 (18) 9 (11) 12 (15) 7 (8) 62
Nosocomial RSV
(11)
1 (10) 1 (9) 2 (5) 0 (0) 3 (13) 3 (8) 1 (6) 1 (3) 8 (10) 4 (5) 5 (6) 34
Underlying medical conditions
Lung disease
16 (36) 4 (40) 7 (64) 14 (33) 8 (36) 8 (33) 12 (32) 9 (50) 17 (50) 32 (40) 34 (44) 38 ( 6 (60) 6 (55) 22 (51) 7 (32) 13 (54) 11 (30) 6 (33) 11 (32) 35 (43) 29 (37) 39 (45) 194
Chemotherapy <30 d
8 (18) 1 (10) 2 (18) 10 (23) 6 (27) 4 (17) 7 (19) 2 (11) 3 (9) 16 (20) 9 (12) 15 (17) 83 SCT <1 y 3 (7) 0 (0) 0 (0) 5 (12) 3 (14) 2 (8) 3 (8) 0 (0) 1 (3) 5 (6) 3 (4) 16 (18) 41 Diabetes
(31)
3 (30) 4 (36) 9 (21) 7 (32) 6 (25) 9 (24) 7 (39) 11 (32) 18 (22) 25 (32) 20 (23) 133
Cardiac disease
(36)
3 (30) 2 (18) 12 (28) 10 (45) 6 (25) 10 (27) 8 (44) 7 (21) 28 (35) 36 (46) 30 (34) 168 Rheum disease
(16)
0 (0) 2 (18) 10 (23) 3 (14) 7 (29) 4 (11) 3 (17) 6 (18) 13 (16) 11 (14) 13 (15) 79
Renal disease 8 (18) 0 (0) 0 (0) 8 (19) 4 (18) 5 (21) 9 (24) 3 (17) 11 (32) 21 (26) 20 (26) 18 (21) 107 SOT
(9)
0 (0) 1 (9) 4 (9) 2 (9) 0 (0) 1 (3) 4 (22) 3 (9) 3 (4) 2 (3) 6 (7) 30 Immunosuppression 18 (40) 5 (50) 7 (64) 14 (33) 7 (32) 10 (42) 12 (32) 7 (39) 12 (35) 29 (36) 28 (36) 37 (43) 186
Abnormal CXR
21 (47) 4 (40) 6 (55) 14 (33) 8 (41) 10 (42) 14 (38) 5 (28) 11 (32) 28 (35) 33 (42) 35 (40) 190
Presenting symptoms Cough
40 (89) 7 (70) 10 (91) 39 (91) 20 (91) 20 (83) 28 (76) 16 (89) 30 (88) 72 (89) 68 (87) 74 (85) 424 Fevers 24 (53)
9 (90) 1 (9) 23 (53) 13 (59) 9 (38) 16 (43) 10 (56) 14 (41) 29 (36) 28 (36) 32 (37)
208
Shortness of breath
(42)
4 (40) 5 (45) 17 (40) 11 (50) 11 (46) 16 (43) 7 (39) 9 (26) 32 (40) 32 (41) 24 (28) 187 Nasal congestion
(24)
3 (30) 0 (0) 17 (40) 7 (32) 5 (21) 7 (19) 5 (28) 1 (3) 18 (22) 19 (24) 22 (25) 115 Rhinorrhea
(13)
2 (20) 2 (18) 8 (19) 5 (23) 5 (21) 1 (3) 5 (28) 5 (15) 19 (23) 17 (22) 22 (25) 97 Chills 9 (20) 1 (10) 0 (0) 10 (23) 4 (18) 7 (29) 4 (11) 2 (11) 5 (15) 15 (19) 14 (18) 16 (18) 87 Sore throat
13 (29) 3 (30) 0 (0) 7 (16) 3 (14) 5 (21) 4 (11) 3 (17) 3 (9) 12 (15) 14 (18) 12 (14) 79 Fatigue 9 (20) 2 (20) 0 (0) 8 (19) 4 (18) 1 (4) 5 (14) 1 (6) 4 (12) 10 (12) 10 (13) 13 (15) 67
Myalgias
(9)
2 (20) 2 (18) 12 (28) 4 (18) 4 (17) 8 (22) 1 (6) 4 (12) 10 (12) 8 (10) 7 (8) 66
Headache
(4)
1 (10) 2 (18) 3 (7) 0 (0) 3 (13) 5 (14) 1 (6) 3 (9) 4 (5) 11 (14) 9 ( virus testing performed; rates of performed test increased over the study period with the largest increases the last two seasons. Of the hospitalized RSV-infected patients, 46% (n = 227) had RSV A and 54% (n = 262) had RSV B; 60.5% were female and the mean age was 60 years (SD 17; see Table 1 ). Most (93.3%) RSV-infected patients had a history of at least one medical comorbidity, while the most common comorbidities were chronic lung disease (40.6%), obesity (BMI ≥ 30, 37.8%), and cardiac disease (34.3%). Over a third of patients were taking an immunosuppressive medication (39.6%) or had a history of smoking (39.6%). While lung disease was the most common comorbidity, obstructive lung disease (83.5%) made up a majority of these patients, followed by other chronic lung illnesses (eg, active or prior lung cancer, pulmonary embolism, or abscess) (10.7%), restrictive lung disease (4.6%), and mixed obstructive/restrictive (1.5%).
| Clinical presentation
The most common symptom on presentation was cough (86.5%), fever (42.4%), shortness of breath (38.2%), nasal congestion (23.5%), and rhinorrhea (19.7%). Chest imaging on admission had documentation of pulmonary infiltrate in 190 patients (38.8%).
The median time between onset of symptoms and admission 
| Management and outcomes
Supplemental oxygen was utilized in 44.6% (218) patients with an additional 11.9% (58) requiring non-invasive ventilation, such as CPAP, and 12.3% (60) requiring mechanical ventilation at some point during their hospitalization (see Table 2 ). Most (76.3%, 374)
patients were administered at least one dose of antibiotics dur- 1 (10) 2 (18) 6 (14) 8 (36) 2 (8) 8 (22) 2 (11) 8 (24) 14 (17) 10 (13) 7 (8) 72
Renal replacement 4 (9)
(9)
5 (21) 5 (14) 1 (6) 3 (9) 6 (7) 1 (1) 5 ( 
(91)
18 (75) 26 (70) 13 (72) 22 (65) 53 (65) 47 (60) 48 ( 
(45)
(28)
(36)
8 (33) 11 (30) 6 (33) 8 (24) 19 (23) 19 (24) 18 ( 
(23)
3 (13) 6 (16) 4 (22) 3 (9) 8 (10) 8 (9) 3 (3)
58
Intubation
(16)
(0)
4 (37) 6 (14) 4 (18) 7 (29) 5 (14) 4 (22) 4 (12) 8 (10) 8 (10)
(6) 60
Outcome
Discharge home
(78)
9 (90) 7 (64) 35 (81) 17 (77) 19 (79) 30 (81) 14 (78) 29 (85) 66 (81) 65 (83) 79 (92) 405
Other medical facility 8 (18) 1 (10) 4 (36) 6 (14) 2 (9) 3 (13) 6 (16) 4 (22) 2 (6) 13 (16) 7 (9) 7 (8) 63 Death 2 (4)
3 (14) 2 (8) 1 (3) 0 (0) 2 (6) 2 (2) 4 (5) 1 (1) 19 patients had ICU admissions ≥30 days) and the median number of days of mechanical ventilation was six (range 1-77 days). Oncology and hematopoietic stem cell transplant recipients had a lower rate of ICU admission and hospitalization compared to the general population (see Table S2 ). Table S1 for details). Oncology and hematopoietic stem cell transplant recipients had a higher mortality rate than the general population (see Table S2 ).
| Risk factors for outcomes
Shortness of breath on presentation (52.6% vs 33.3%, P < 0.001) was associated with severe disease while cough (91.5% vs 76.3%, P < 0.001), rhinorrhea (23.4% vs 10.4%, P = 0.002), nasal congestion (27.7% vs 11.1%, P < 0.001), and myalgias (15.8% vs 7.4% P = 0.022) on presentation were less likely to develop severe disease (see Table 3 ).
No pre-existing condition was significantly over-represented in patients requiring ICU admission, although the presence of a co-infection (26.5% vs 10.6%, P < 0.001) was more common among ICU admissions.
No factor was statistically associated with intubation, although there was a trend toward higher rates of intubation in patients with cancer treatment, diabetes, and a documented co-infection (see Table 4 ).
Age >65 (58.7% vs 37.3%, P = 0.002), the presence of chronic cardiac disease (52.4% vs 32.9%, P = 0.004), and the presence of co-infection (25.4% vs 12.8%, P = 0.014) were associated with discharge to a skilled nursing of rehabilitation facility (see Table 4 ).
Fatal cases occurred more frequently in patients with recent cancer treatment (42.1% vs 16.2%, P = 0.009) and patients with age >65
(68.4% vs 40.2%, P = 0.027).
| D ISCUSS I ON
This study represents one of the largest studies of RSV in hospitalized adults with patients sampled over multiple seasons. About a quarter of patients required ICU level care, and death was more common among those with recent cancer treatment and age >65 years.
Most patients were given antibacterial therapy during hospitalization with almost half being discharged on antibiotics despite limited documentation of concomitant bacterial infection. These data provide important insight into the epidemiology and outcomes of RSV in hospitalized adults in the contemporary era.
The inclusion of six seasons worth of data provides insight into the seasonal variability of RSV in hospitalized adults. There was no significant variation in demographics, treatment, or outcomes by season or predominating RSV type. While most previous studies have found annual alternation between RSV A and RSV B, our data suggest a 3-year cycle to be common as well (A predominant, B predominant, mixedtype seasons). [20] [21] [22] [23] Although RSV circulation patterns tend to be local, future studies are needed to define the degree of regional variability of predominating type. Most patients were documented in the typical winter respiratory virus months (November-April). Such data will be helpful in the design of clinical studies and for assessments of the impact of future vaccine or treatments for RSV.
The finding that nasal congestion, rhinorrhea, cough, and myalgias were associated with a lack of severe disease may help identify patients who may require less supportive measures and can be discharged more quickly. Likewise, the association between older age, prior cardiac disease, and co-infection and need for higher level of care on discharge likewise may help risk stratify patients on In comparison with other studies, this study suggests similar data regarding symptoms at presentation, median length of stay, and rates of co-infection, antimicrobial therapy, and death. The patients in our study were somewhat younger than other studies that included hospitalized adults as well. 17, 18 However, our study suggests that rates of ICU admission and mechanical ventilation were higher overall than what is previously described. 17 The relatively high proportion of immunocompromised patients included in this study may, in part, explain this high rate of ICU admission and ventilator use.
The time from symptom onset to presentation was also similar to what has been documented in other studies. 18 Additionally, the finding that ICU and intubation rates were lower among patients with recent chemotherapy or HSCT compared to healthier patients is interesting. While death rates were higher in the immunocompromised patients, other risk factors such as underlying lung disease may play a larger role in respiratory decompensation. It is also possible that the immunocompromising conditions result in less inflammation which could be protective against the need for ICU care or intubation. Intubation is associated with higher mortality in immunocompromised patients, and the lower rate may be due to avoidance of invasive procedures in these populations. 24 The lower death rate among healthy individuals is otherwise unremarkable given the inherent physiologic reserve these patients may have to rebound from illness.
An interesting finding is that patients who died had a longer period of time between symptom onset and diagnostic testing.
The reason for this is not entirely obvious with the data collected in this study. The likely factor that was difficult to obtain in the lations is more at the discretion of the admitting physician. 25 Lastly, as this is a single-center study, unique features of our center or location may affect the findings of this study and future studies in other regions are needed to confirm our findings.
Another finding of this study is that despite the availability of rapid molecular diagnostic methods, empiric antibacterial therapy was prescribed to a significant portion of RSV-positive patients de- While this study generally confirmed many of the findings of older studies, it is one of the largest studies using contemporary molecular diagnostics on a large population of RSV-infected hospitalized adults. As such, it provides insight that will become increasingly important as a diagnosis of RSV may soon have therapeutic implications with many such agents actively undergoing study. 
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